Intellia Therapeutics, Inc. (NTLA) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped NTLA stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Intellia Therapeutics offers significant upside due to its high revenue growth potential, recent clinical trial successes, strong industry partnerships, and positive analyst sentiment. Key risks include regulatory challenges and competition; however, the company's gene editing innovations and market adaptability position it favorably for substantial returns in the medium-to-long term. The saved 1-year distribution is P10 $10.2, P50 $15.5, and P90 $25.
Last analyzed · Model: gpt-4o
Intellia Therapeutics, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $10.2 | Pessimistic plausible scenario |
| P50 | $15.5 | Median scenario |
| P90 | $25 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Intellia Therapeutics shows strong potential for price appreciation in the upcoming year, supported by recent positive trial results for NTLA-2001 and a promising revenue growth estimate. However, regulatory risks and skepticism in some quarters temper the bullish outlook.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this NTLA analysis generated?
April 11, 2026.
Is this a guaranteed NTLA prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full NTLA stock analysis · NTLA sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.